Elderly May Not Reap Post-MI Ticagrelor Advantage vs Clopidogrel Elderly May Not Reap Post-MI Ticagrelor Advantage vs Clopidogrel
The PLATO trial's seminal results a decade ago may not apply to all patients after a myocardial infarction; a large registry study suggests no ticagrelor benefit, perhaps even harm, in older patients.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 9, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Aspirin Alone Preferred Antithrombotic Strategy After TAVI Aspirin Alone Preferred Antithrombotic Strategy After TAVI
Aspirin alone after TAVI significantly reduced bleeding compared with aspirin plus clopidogrel, without increasing thromboembolic events, in the latest results from the POPular TAVI study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 30, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Fewer GI Bleeds With Ticagrelor and Prasugrel After PCI Fewer GI Bleeds With Ticagrelor and Prasugrel After PCI
In a comparison of post-PCI antiplatelet medications, ticagrelor or prasugrel were associated with fewer GI bleeding events than clopidogrel.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 26, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Antithrombotic Therapies in COVID-19 Disease: a Systematic Review
Conclusion(s): New evidence on thromboembolism in COVID-19 does not warrant a change in current guidance on thromboprophylaxis among hospitalized patients. Prospective trials of antithrombotic treatment strategies among patients with COVID-19 are urgently needed. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 1, 2020 Category: Consumer Health News Source Type: news

ACC Virtual Scientific Sessions 2020: Interventional Strategies Highlights ACC Virtual Scientific Sessions 2020: Interventional Strategies Highlights
Genetic testing for clopidogrel resistance and a new strategy for atrial fibrillation ablation are among the highlights from the virtual ACC scientific sessions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 28, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Mislabeled Clopidogrel Lot Recalled, May Contain Simvastatin Mislabeled Clopidogrel Lot Recalled, May Contain Simvastatin
International Laboratories has recalled one lot of clopidogrel tablets packaged in bottles of 30 tablets because it may contain simvastatin instead of clopidogrel.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 17, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news

TAILOR-PCI and the Role of Genotype-Guided Antiplatelet Therapy TAILOR-PCI and the Role of Genotype-Guided Antiplatelet Therapy
Investigators from the TAILOR PCI trial that used point-of-care genomic testing to identify clopidogrel nonresponders discuss the take-homes and why genotyping may be better than platelet function tests.Mayo Clinic (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 7, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news

VOYAGER PAD: Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin
Adding clopidogrel added no efficacy but caused additional bleeding episodes. (Source: WebMD Health)
Source: WebMD Health - April 6, 2020 Category: Consumer Health News Source Type: news

VOYAGER PAD: Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin VOYAGER PAD: Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin
Adding clopidogrel added no efficacy but caused additional bleeding episodes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 3, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Safe to Skip Post-TAVR Clopidogrel in Patients on OAC for AF Safe to Skip Post-TAVR Clopidogrel in Patients on OAC for AF
The bleeding risk went up in such patients on oral anticoagulation who then added clopidogrel in POPULAR-TAVI, and being on OAC alone didn't raise ischemic risk. Some experts question its methods.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 30, 2020 Category: Surgery Tags: Cardiology News Source Type: news

Clopidogrel atop rivaroxaban and aspirin shows no added benefit for PAD
(American College of Cardiology) The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization -- a procedure to treat blocked arteries in the leg -- had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to a subgroup analysis from VOYAGER PAD presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news

TAILOR-PCI: Clopidogrel Genotyping Trial Narrowly Misses Endpoint TAILOR-PCI: Clopidogrel Genotyping Trial Narrowly Misses Endpoint
The trial missed its ambitious primary endpoint of a 50% reduction in cardiovascular events, but commentators felt nonetheless that it shows a clinical benefit and should change practice.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 28, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefi...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

More Concern Over Morphine, Clopidogrel Interaction in ACS More Concern Over Morphine, Clopidogrel Interaction in ACS
New data suggest use of morphine delays the absorption of clopidogrel and leads to an increase in short-term cardiac ischemic events.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 23, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Clopidogrel Appropriate for PCI in Liver Transplant Candidates Clopidogrel Appropriate for PCI in Liver Transplant Candidates
In patients with decompensated cirrhosis undergoing percutaneous coronary intervention (PCI), clopidogrel safely inhibits platelet aggregation, according to a small study of liver-transplant candidates.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 8, 2020 Category: Surgery Tags: Cardiology News Source Type: news

Genetic Testing Spots Clopidogrel Responders After PCI for STEMI Genetic Testing Spots Clopidogrel Responders After PCI for STEMI
Guidelines for the management of acute STEMI patients undergoing PCI may need to be revised after a genotype-guided protocol giving clopidogrel to responders reduced bleeding rates, say experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 3, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Optimal Dual Antiplatelet Duration After Minor Stroke or TIA? Optimal Dual Antiplatelet Duration After Minor Stroke or TIA?
Pooled data from two large trials points to a net benefit associated with 21 days of clopidogrel – aspirin therapy after a minor stroke or transient ischemic attack.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 29, 2019 Category: Intensive Care Tags: Neurology & Neurosurgery News Source Type: news

Ultrasound-Guided Thoracentesis Appears Safe With Novel Oral Anticoagulants or Clopidogrel Ultrasound-Guided Thoracentesis Appears Safe With Novel Oral Anticoagulants or Clopidogrel
Rates of significant bleeding complications are very low after ultrasound-guided thoracentesis in patients on novel oral anticoagulants (NOACs) and/or clopidogrel, a retrospective analysis found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 6, 2019 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

clopidogrel bisulfate (Plavix)
Title: clopidogrel bisulfate (Plavix)Category: MedicationsCreated: 6/6/1999 12:00:00 AMLast Editorial Review: 7/30/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - July 30, 2019 Category: Cardiology Source Type: news

Plavix (clopidogrel) vs. Xarelto (rivaroxaban)
Title: Plavix (clopidogrel) vs. Xarelto (rivaroxaban)Category: MedicationsCreated: 7/19/2019 12:00:00 AMLast Editorial Review: 7/19/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - July 19, 2019 Category: Cardiology Source Type: news

Plavix (clopidogrel) vs. Effient (prasurgrel)
Title: Plavix (clopidogrel) vs. Effient (prasurgrel)Category: MedicationsCreated: 7/19/2019 12:00:00 AMLast Editorial Review: 7/19/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - July 19, 2019 Category: Cardiology Source Type: news

Antithrombotic agents and traumatic brain injury in the elderly population: hemorrhage patterns and outcomes - Scotti P, S ├ęguin C, Lo BWY, De Guise E, Troquet JM, Marcoux J.
OBJECTIVE: Among the elderly, use of antithrombotics (ATs), antiplatelets (APs; aspirin, clopidogrel), and/or anticoagulants (ACs; warfarin, direct oral ACs [DOACs; dabigatran, rivaroxaban, apixaban]) to prevent thromboembolic events must be carefully weig... (Source: SafetyLit)
Source: SafetyLit - July 8, 2019 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Plavix (clopidogrel) vs. Coumadin (warfarin)
Title: Plavix (clopidogrel) vs. Coumadin (warfarin)Category: MedicationsCreated: 6/25/2019 12:00:00 AMLast Editorial Review: 6/25/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 25, 2019 Category: Cardiology Source Type: news

clopidogrel (Plavix) vs. heparin (Hemochron)
Title: clopidogrel (Plavix) vs. heparin (Hemochron)Category: MedicationsCreated: 6/24/2019 12:00:00 AMLast Editorial Review: 6/24/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 24, 2019 Category: Cardiology Source Type: news

Restarting Antiplatelet After ICH Cuts Recurrence Risk in Half Restarting Antiplatelet After ICH Cuts Recurrence Risk in Half
Restarting antiplatelet therapy after intracranial hemorrhage remains controversial, but new evidence suggests aspirin or clopidogrel can significantly reduce recurrent ICH without increased bleeding.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 23, 2019 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Aspirin, Anti-Clotting Meds Safe After Bleeding Stroke: Study
WEDNESDAY, May 22, 2019 -- Taking aspirin or anti-clotting medicines like Plavix won't boost the risk of another stroke if you've already survived a bleeding stroke, a new study suggests. In fact, they might even help guard against a second brain... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 22, 2019 Category: General Medicine Source Type: news

International Laboratories, LLC Issues Voluntary Nationwide Recall of one (1) Lot of Clopidogrel Tablets USP, 75 mg packaged in bottles of 30 tablets Due to Mislabeling NDC # 54458-888-16; Lot # 117099A
International Laboratories, LLC is voluntarily recalling Lot# 117099A of Clopidogrel Tablets, USP 75 mg, packaged in bottles of 30 tablets, to the consumer level due to mislabeling. The product is labeled as Clopidogrel tablets USP 75 mg but may contain Clopidogrel 75mg or Simvastatin Tablets USP 10 mg. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 21, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

New Studies Support Dropping Long-term Aspirin After Stenting New Studies Support Dropping Long-term Aspirin After Stenting
The STOPDAPT-2 and SMART-CHOICE trials both suggest extended therapy with clopidogrel or another P2Y12 inhibitor alone may be preferable to dual antiplatelet therapy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 28, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Ticagrelor is as safe and effective as clopidogrel after heart attack
(American College of Cardiology) Patients given clot busters to treat a heart attack fared equally well if they were given the standard blood thinning medication clopidogrel versus the newer, more potent drug ticagrelor, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 18, 2019 Category: International Medicine & Public Health Source Type: news

Stopping aspirin three months after stenting does not increase risk of death
(American College of Cardiology) Patients who stopped taking aspirin three months after receiving a stent to open the heart's arteries but continued taking a P2Y12 inhibitor -- clopidogrel, prasugrel or ticagrelor -- did not experience higher rates of death from any cause, heart attack or stroke after a year compared with those receiving standard therapy, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. Furthermore, patients who stopped taking aspirin after three months had a significantly lower rate of bleeding. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 18, 2019 Category: International Medicine & Public Health Source Type: news

Stopping DAPT after one-month improved outcomes in stent patients
(American College of Cardiology) Patients who stopped taking aspirin one month after receiving a stent in the heart's arteries but continued taking the P2Y12 inhibitor clopidogrel fared significantly better after one year compared with those who followed the standard practice of continuing both medications, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 18, 2019 Category: International Medicine & Public Health Source Type: news

Drug May Be Safer Option Against Repeat Stroke
The risk of another stroke caused by a blood clot was halved for patients who took the drug Pletal plus aspirin or clopidogrel, versus those who took aspirin or clopidogrel alone. (Source: WebMD Health)
Source: WebMD Health - February 7, 2019 Category: Consumer Health News Source Type: news

Dual Antiplatelet Therapy With Cilostazol Cuts Recurrent Stroke Dual Antiplatelet Therapy With Cilostazol Cuts Recurrent Stroke
New results show cilostazol plus aspirin or clopidogrel reduced recurrent stroke rate by half over aspirin or clopidogrel alone in high-risk stroke patients without increased bleeding.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 7, 2019 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Blood Thinning Drug May Be Safer Option Against Recurrent Stroke
THURSDAY, Feb. 7, 2019 -- Taking the blood thinner Pletal (cilostazol) with either aspirin or clopidogrel (best known as Plavix) lowers stroke patients'risk of a subsequent stroke better than taking aspirin or clopidogrel alone, a new study... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 7, 2019 Category: General Medicine Source Type: news

Cilostazol-combo antiplatelet therapy reduced risk for recurrent stroke
(American Heart Association) The long-term combination of cilostazol with aspirin or clopidogrel resulted in fewer recurrent strokes than with aspirin or clopidogrel alone in high-risk patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 6, 2019 Category: International Medicine & Public Health Source Type: news

Clopidogrel vs aspirin in acute coronary syndrome in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news

Risk of Adverse CV Events With PPIs Independent of Clopidogrel Risk of Adverse CV Events With PPIs Independent of Clopidogrel
This study aimed to determine whether the observed increase in cardiovascular risk of PPI use with anti-platelet therapy is conferred by PPIs directly or by a pharmacokinetic interaction.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 26, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Modern antiplatelet therapy: When is clopidogrel the right choice?
(Cardiovascular Innovations and Applications) In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 2, 2018, pp. 149-162(14); DOI: 10.15212/CVIA.2017.0049 Punag Divanji and Kendrick Shunk from the University of California San Francisco and The San Francisco Veteran Affairs Hospital, San Francisco, Calif., USA consider when clopidogrel is the right choice in modern antiplatelet therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2018 Category: International Medicine & Public Health Source Type: news

Plavix and TTP
Title: Plavix and TTPCategory: Doctor's& Expert's views on SymptomsCreated: 5/10/2000 4:41:00 PMLast Editorial Review: 6/13/2018 2:55:08 PM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 13, 2018 Category: Drugs & Pharmacology Source Type: news

Stroke After PCI Linked to Platelet Reactivity on Plavix
(MedPage Today) -- But it's unclear whether link seen in post hoc analysis would be actionable (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 7, 2018 Category: Cardiology Source Type: news

Many Prescriptions for Newer, More Expensive Antiplatelet Agents Go Unfilled Many Prescriptions for Newer, More Expensive Antiplatelet Agents Go Unfilled
Prescriptions for the P2Y12 inhibitors prasugrel hydrochloride and ticagrelor hydrochloride after percutaneous coronary intervention (PCI) are outpacing those for clopidogrel, but many patients are not filling those prescriptions, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

POINT: Success at Last for Dual Antiplatelet After Stroke, TIA POINT: Success at Last for Dual Antiplatelet After Stroke, TIA
A combination of clopidogrel plus aspirin reduced major ischemic events vs aspirin alone in patients with minor ischemic stroke or high-risk TIA in this long-awaited trial.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Clopidogrel & #43; Aspirin Cuts Ischemic Events in Stroke, TIA
THURSDAY, May 17, 2018 -- The combination of clopidogrel and aspirin is associated with reduced risk of major ischemic events but increased risk of major hemorrhage among patients with minor ischemic stroke or high-risk transient ischemic attack... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 17, 2018 Category: Pharmaceuticals Source Type: news

International study suggests combination therapy may prevent stroke in certain people
(NIH/National Institute of Neurological Disorders and Stroke) Results from an international clinical trial of more than 4880 participants, published in the New England Journal of Medicine, show that combining clopidogrel and aspirin following a small stroke or experiencing minor stroke symptoms decreases risk of a new stroke, heart attack or other ischemic event within 90 days. The combination therapy was also associated with an increase in major bleeding, although many of those episodes were non-fatal and did not occur in the brain. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 17, 2018 Category: International Medicine & Public Health Source Type: news

After'Mini-Stroke,' Drug Combo (Aspirin Plus Clopidogrel) Could Help Cut Odds for Major Attack
WEDNESDAY, May 16, 2018 -- A dual-drug approach after a " mini-stroke " might maximize a person's odds of avoiding a more major stroke in the months after, research shows. Minor strokes and events known as " transient ischemic attacks " (TIA), or... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 16, 2018 Category: General Medicine Source Type: news

Stroke prevention drug combo shows promise
If you've had a minor stroke or a transient ischemic stroke (TIA), taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days, according to new research published in The New England Journal of Medicine. (Source: World Pharma News)
Source: World Pharma News - May 16, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Stroke prevention drug combo shows promise, study says
(University of Texas at Austin) If you've had a minor stroke or a transient ischemic stroke (TIA), taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days, according to new research published in The New England Journal of Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 16, 2018 Category: International Medicine & Public Health Source Type: news

Routine Genotyping for Clopidogrel Response Sustainable in Practice (CME/CE)
(MedPage Today) -- Group's findings support use, but impact remains unproven in trials (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 3, 2018 Category: Cardiology Source Type: news

AHA: Gene Test Predicts Who Won't Benefit From Blood Thinner Plavix
TUESDAY, April 3, 2018 (American Heart Association) -- Heart stent patients with a certain gene mutation may need to consider alternatives to Plavix, a commonly prescribed blood thinner, a new study suggests. Researchers reported Tuesday that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 3, 2018 Category: General Medicine Source Type: news